CT/NG Testing Market worth $2.7 billion | MarketsandMarkets
/PRNewswire/ -- In the near future, the CT/NG (Chlamydia and Gonorrhea) testing industry is poised to witness significant advancements and transformations....
Stay updated with breaking news from Molbio Diagnostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- In the near future, the CT/NG (Chlamydia and Gonorrhea) testing industry is poised to witness significant advancements and transformations....
/PRNewswire/ -- The molecular diagnostics industry is poised to undergo significant advancements in the near future, fueled by rapid technological innovation...
Cyient DLM IPO has been subscribed 14.52 times so far on the last day of bidding, with retail investors leading the way. The retail investors' portion got subscribed 37.39 times, the non-institutional investors' quota 23.83 times, and the qualified institutional buyers' portion received 3.44 times bids more than the reserved amount. The company's shares are commanding a premium of Rs 110-112 compared to the upper end of the price band. Cyient DLM is an electronic manufacturing services provider with long-term relationships with key customers. Analysts believe the company's valuation is in line...
In 2021, the global Infectious Disease Molecular Diagnostics Market was estimated to be worth approximately US$ 34 billion. With a projected CAGR of 4.2% over the next ten years, the market is expected to be worth nearly US$ 53 billion by the end of 2032. Rather than the traditional methods that required pathogen cu...
Integrated electronic manufacturing services provider, Cyient DLM, witnessed strong demand for its IPO, with the overall issue being subscribed 4.76 times on the second day. Retail investors showed significant interest with a subscription of 17.10 times, while the demand from qualified institutional buyers remained muted at just 4%. According to analysts, the company's shares are expected to command a premium and potentially fetch a bumper premium of 41% on listing. Cyient DLM reported revenue growth of 15% and a profit of Rs 31.7 crore for the financial year ending March 2023.